[The clinical assessment of the results of predicting individual sensitivity to adjuvant chemotherapy in lung tumors].
The value of subrenal capsule assay for predicting individual chemoresistance of tumor was evaluated using samples from 32 lung carcinomas. Treatment with drugs which had proved effective in the test was followed by a recurrence-free period of 15.5 +/- 3.7 months, as compared to 8.0 +/- 1.0 months for patients receiving ineffective drugs.
Sergeeva
N S
NS
Skotnikova
O I
OI
Chissov
V I
VI
Borisov
V I
VI
Trakhtenberg
A Kh
AKh
Bil'danova
L A
LA
Pelevina
I I
II
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008808:Mice, Inbred CBA; D009367:Neoplasm Staging; D011379:Prognosis; D013370:Subrenal Capsule Assay
D000970:Antineoplastic Agents
Klinicheskaia otsenka rezul'tatov prognozirovaniia individual'noĭ chuvstvitel'nosti k ad''iuvantnoĭ khimioterapii opukholeĭ legkogo.